Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Finasteride, a drug that changes testosterone to a different hormone, was studied and its effects over time were modeled successfully.

Finasteride reduces prostate size and symptoms with few side effects.

This theoretical study suggests that certain cannabinoid derivatives could potentially be effective as androgen receptor and 5α-reductase enzyme inhibitors, indicating they may be promising candidates for prostate cancer treatment based on their higher affinity to target proteins compared to standard drugs.

In a rat model of benign prostatic hyperplasia, this study found that purple corn extract may improve symptoms by inhibiting prostate enlargement, reducing androgen receptor signaling, and exerting anti-inflammatory effects.

This study found that among men with Benign Prostatic Hyperplasia, treatment with the 5α-reductase inhibitor finasteride for three months significantly reduced levels of dihydrotestosterone and estradiol, hormones involved in prostate enlargement, without altering follicle-stimulating hormone or luteinizing hormone levels.

This study designed a novel model for 5a-reductase enzyme inhibitors using pharmacophore and 3D QSAR techniques, potentially allowing for improved prediction and development of drug therapies targeting benign prostatic hyperplasia.

This study investigates the potential of onion extract as a treatment for androgenetic alopecia by using in silico and ADME/T analyses to examine how active compounds from onions interact with the 5-alpha-reductase enzyme.

This article presents a case of 5-alpha-reductase deficiency in a Saudi individual, reporting no new research findings.

This review reports that 5-alpha reductase inhibitors, used to treat androgenic alopecia, may adversely affect sperm count, sexual function, and hormones in a subset of patients.

5-alpha reductase inhibitors do not increase osteoporosis risk in women with certain hair loss conditions.

This integrative literature review suggests that phytotherapeutic products, like Saw palmetto and Green tea, could serve as viable alternatives to current medications like finasteride for treating androgenetic alopecia, potentially offering fewer side effects.

This study reported that a novel cationic liposome formulation for delivering encapsulated Cas9 protein and sgRNA successfully decreased SRD5α2 mRNA expression by 29.7% in vitro, suggesting a potential alternative treatment option for conditions like prostate cancer and benign prostatic hyperplasia without current drug side effects.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study found that finasteride treatment may decrease contraction of seminal vesicle tissue and alter some semen parameters in male rabbits.

This study reported that cognitive biopsy diagnosed prostate cancer in 44% of patients with at least one previous negative biopsy, with higher detection rates in lesions classified as PI-RADS 4 and 5.

This historical review traces the discovery of 5-alpha reductase inhibitors, widely used in urology, from the study of guevedoces, Dominican children with a rare disorder leading to significant androgenization at puberty.

This review discusses the roles of dihydrotestosterone in fetal development and adult diseases, reporting no new clinical results; the authors emphasize the potential of 5α-reductase inhibitors for treatment.

This review highlights the use of finasteride, a 5alpha-reductase inhibitor, for treating benign prostatic hyperplasia and male pattern hair loss, noting that it may cause male sexual dysfunction but usually with tolerable side effects that decrease over time, not requiring treatment discontinuation.

This article reviews updates on 5 alpha-reductase inhibitors for treating male pattern hair loss and presents no new clinical findings; the author aims to enhance understanding of these therapies.

This study identified LY191704 as a specific noncompetitive inhibitor of human 5 alpha-reductase type 1, which may be useful in treating endocrine disorders related to DHT overproduction.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

This article discusses the potential use of 5α-reductase inhibitors in dermatology and reports no new clinical results; the authors suggest further exploration of their dermatological applications.

This study reports that the compound CS-891 can inhibit 5alpha-reductase activity in the dermal papillae of human hair follicles, suggesting potential for treating androgenetic alopecia.

This review highlights the challenges in screening for steroid 5 alpha-reductase inhibitors and discusses significant variability in the effectiveness of finasteride and dutasteride, calling for standardized testing methods to develop safer, more specific inhibitors from herbal preparations.

In this study, the SRD5A2 rs523349 polymorphism was significantly associated with an increased risk of miscarriage, particularly during the second trimester.

This study found that intracrine androgen signaling via 5α-reductase is essential for optimal endometrial decidualization and vascular development during this process in mice.

This study found that intracrine androgen signaling, mediated by steroid 5α-reductase, is essential for optimal decidualization and vascular development in the endometrium during pregnancy, indicating potential targets for improving age-related fertility issues.

This study details the isolation and characterization of the human type II 5 alpha-reductase gene, which may play a role in male pseudohermaphroditism, prostate cancer, and benign prostatic hyperplasia.